Show source-provided references
2. 3D bioprinting spatiotemporally defined patterns of growth factors to tightly control tissue regeneration
10.1126/sciadv.abb5093 ↗4. Recapitulating bone development through engineered mesenchymal condensations and mechanical cues for tissue regeneration
10.1126/scitranslmed.aav7756 ↗7. Enhanced osteogenesis of hydroxyapatite scaffolds by coating with BMP-2-loaded short polylactide nanofiber: a new drug loading method for porous scaffolds
9. A proton-responsive ensemble using mesocellular foam supports capped with N, O-carboxymethyl chitosan for controlled release of bioactive proteins
10.1039/C5TB00219B ↗10. Heparin-mediated delivery of bone morphogenetic protein-2 improves spatial localization of bone regeneration
10.1126/sciadv.aay1240 ↗11. A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein-2 and zoledronic acid
10.1126/sciadv.abc1779 ↗12. Multifunctional scaffolds for facile implantation, spontaneous fixation, and accelerated long bone regeneration in rodents
10.1126/scitranslmed.aau7411 ↗15. Fabrication and clinical application of easy-to-operate pre-cured CPC/rhBMP-2 micro-scaffolds for bone regeneration
16. Induction of bone formation by 3D biologically active scaffolds containing RGD-NPs, BMP2, and NtMPCs
10.1002/adtp.202000245 ↗17. Enhancement of BMP-2 and VEGF carried by mineralized collagen for mandibular bone regeneration
10.1093/rb/rbaa022 ↗18. Engineered bridge protein with dual affinity for bone morphogenetic protein-2 and collagen enhances bone regeneration for spinal fusion
10.1126/sciadv.abh4302 ↗19. Lysostaphin and BMP-2 co-delivery reduces S. aureus infection and regenerates critical-sized segmental bone defects
10.1126/sciadv.aaw1228 ↗20. A BMP/activin A chimera is superior to native BMPs and induces bone repair in nonhuman primates when delivered in a composite matrix
10.1126/scitranslmed.aar4953 ↗21. Sialic acid-modified dexamethasone lipid calcium phosphate gel core nanoparticles for target treatment of kidney injury
10.1039/D0BM00581A ↗22. Bone morphogenetic protein 2 and dexamethasone synergistically increase alkaline phosphatase levels through JAK/STAT signaling in C3H10T1/2 cells
10.1002/jcp.22017 ↗23. Dexamethasone modulates BMP-2 effects on mesenchymal stem cells in vitro
10.1002/jor.20565 ↗24. Injectable mechanical pillows for attenuation of load-induced post-traumatic osteoarthritis
10.1093/rb/rbz013 ↗25. Controlled dual delivery of BMP-2 and dexamethasone by nanoparticle-embedded electrospun nanofibers for the efficient repair of critical-sized rat calvarial defect
10.1016/j.biomaterials.2014.10.015 ↗28. Dexamethasone, BMP-2, and 1,25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts
10.1016/j.steroids.2003.12.005 ↗29. Inductive effects of dexamethasone on the mineralization and the osteoblastic gene expressions in mature osteoblast-like ROS17/2.8 cells
10.1016/j.bbrc.2007.07.192 ↗31. High concentrations of dexamethasone suppress the proliferation but not the differentiation or further maturation of human osteoblast precursors in vitro: relevance to glucocorticoid-induced osteoporosis
10.1093/rheumatology/40.1.74 ↗32. Osteoblastic differentiation of human and equine adult bone marrow-derived mesenchymal stem cells when BMP-2 or BMP-7 homodimer genetic modification is compared to BMP-2/7 heterodimer genetic modification in the presence and absence of dexamethasone
10.1002/jor.21126 ↗33. Estrogen and glucocorticoid regulate osteoblast differentiation through the interaction of bone morphogenetic protein-2 and tumor necrosis factor-alpha in C2C12 cells
10.1016/j.mce.2010.05.004 ↗34. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation
10.1016/j.bone.2006.02.074 ↗35. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
10.1038/sj.onc.1203551 ↗36. Molecular basis of the cell specificity of cytokine action
37. BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity
10.1074/jbc.M110.142307 ↗38. Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2
10.1074/jbc.M610997200 ↗40. Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation
10.1242/jcs.02758 ↗41. Down-regulation of type I Runx2 mediated by dexamethasone is required for 3T3-L1 adipogenesis
10.1210/me.2011-1287 ↗43. Runx2 is a common target of transforming growth factor beta 1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12
10.1128/MCB.20.23.8783-8792.2000 ↗44. Interaction and functional cooperation of PEBP2/CBF with Smads - Synergistic induction of the immunoglobulin germline C alpha promoter
10.1074/jbc.274.44.31577 ↗